GE HealthCare (NASDAQ: GEHC) Just Broke Out and Could Soar Up to 30% From Here

GE HealthCare Technologies Inc. (NASDAQ: GEHC) just broke out of a months-long symmetrical triangle on a +6.62% earnings-day gap higher — and looks headed even higher.

As we’ll get to just ahead, the combination of a better-than-expected quarter with raised full-year forecasts, a strategic acquisition that strengthens one of its fastest-growing businesses, and a fresh technical breakout makes GEHC one of the more interesting setups on the board. Here’s what’s going on…

The Themes Behind the Move

GE HealthCare is a Chicago-based medical technology company — spun off from General Electric in early 2023 — that makes the equipment, drugs, and software hospitals use to diagnose, treat, and monitor patients. Its portfolio spans imaging systems (MRI, CT, X-ray, and molecular imaging), ultrasound and image-guided therapy, Patient Care Solutions (patient monitors, anesthesia, and maternal-infant care), and Pharmaceutical Diagnostics — the contrast agents and radioactive “tracers” injected into patients before certain scans.

In plain English, when a hospital needs an MRI or CT scanner, an ultrasound machine, or a bedside patient monitor — or the contrast dyes and tracers that make tumors and heart problems light up on a scan — GE HealthCare is one of the first suppliers on the call list. Its business hinges on hospital equipment budgets, how quickly its higher-growth imaging-drug franchise scales, and whether it can keep expanding margins as it layers AI software on top of its installed base of machines.

GEHC’s latest move reflects a confluence of developments — financial, strategic, and operational — that have come together in rapid succession to reframe the company’s near-term growth trajectory.

If needed, swipe or scroll sideways to view the full table.

Put it all together, and GEHC is looking less like a slow-moving hospital-equipment conglomerate stuck below its long-term averages and more like a margin-expanding healthcare technology franchise — with raised guidance in hand, a $23.7 billion backlog, a fast-growing imaging-drug engine, and a strategic acquisition on deck.

The story is getting stronger, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.

Bullish Technical Signals

#1 Symmetrical Triangle Pattern Breakout: GEHC has broken out of a large symmetrical triangle that has governed price action since late winter, marked in purple on the daily chart. The upper rail has capped every rally since February, falling from roughly $84 to about $72, while the lower rail has risen from the late-April lows near $58 to roughly $65. Each side has made concessions, and the pattern traces a market coiling steadily tighter. The August rally was turned back exactly at the upper trendline, so that line had already proven itself as real supply. Wednesday’s session resolved the coil emphatically. The stock gapped from a $71.11 prior close to a $76.00 open, cleared the trendline in a single stroke, and finished up +6.62% at $75.82. Volume reached 9.57M shares, the heaviest bar since late summer, and that participation shows institutions committing to the breakout rather than retail drifting through it. Projecting the triangle’s widest span (roughly $20) from the breakout zone gives a measured-move objective in the low-$90s, which lines up with the trade’s upside targets. The nuance worth stating plainly is that the session high of $77.88 faded into the close, leaving a lower-wicked but upper-rejected candle beneath $77.20. A daily close above that level is the confirmation the breakout entry is built around.

GEHC – Daily Chart

#2 Price Above 50-MA and 200-MA: The gap carried GEHC decisively above both its 50-day SMA ($68.37) and 200-day SMA ($69.90). The 200-day matters most here. Price had been pinned beneath it for most of October, so reclaiming it on a gap, rather than grinding over it, signals a clean regime change. The two averages are tightly clustered, only about $1.50 apart, and that convergence tells its own story. The 50-day has climbed steadily off its June trough and is now curling toward the 200-day, so a golden cross is plausibly weeks away rather than months. Together, the averages form a defense shelf in the $68–$70 zone, sitting just above the triangle’s former upper rail. The caveat is that price now sits roughly 8–11% above both averages after the gap, so the stock is extended in the near term. This is exactly why the $74.00 pullback entry exists: a retest of the gap zone would be a healthier entry than chasing the opening print.

#3 Bullish ADX and DI: The directional read is as one-sided as this indicator gets. +DI (43.48) has spiked vertically against a sliding –DI (12.28), a spread of more than 31 points. That gap reflects outright buyer dominance, not a marginal tilt. Just as important is the ADX line itself (32.42). It bottomed near 12 in early October, beneath both DI lines, and has climbed steadily since. That pattern, a rise from a suppressed base, is the highest-quality version of an ADX signal. It shows trend strength building from scratch rather than an old trend being re-labeled. With ADX now through the 25 threshold and rising between the two DI lines, GEHC has crossed from “trend forming” into “trend confirmed” while still sitting well short of exhaustion. Stacked against the triangle breakout, the structural trigger and the trend-strength reading are telling the same story.

#4 Bullish MACD: The MACD line (1.64) is running comfortably above its signal line (0.9469), and the histogram (0.6940) is expanding. A widening spread means momentum is accelerating, not merely positive. The sequence behind the signal matters. The bullish crossover first fired in early October just below the zero line, the zone where crossovers tend to carry the most follow-through. Both lines then pushed into positive territory in mid-October. Wednesday’s gap bent the MACD line sharply higher, so the momentum indicator is confirming the breakout rather than lagging or diverging from it. Short-term momentum has now decisively overtaken the longer-term average, which is the classic profile of a move transitioning from repair to advance.

#5 Above Support Area with Downtrend Breakout: The weekly chart shows why this breakout has structural depth. GEHC has rebounded firmly from the $71.72 support area (pink dotted line). That level has flipped between support and resistance repeatedly since 2024, and levels that keep inverting roles are the ones the market respects. This week’s candle tested down to $70.17, was bought back above the line, and closed at $75.82, up +6.12% on the week. That recovery also completed a break above the downtrend line (pink dashed) descending from the early-2026 highs near $88. The confluence is tight. The 50-week SMA ($71.94) sits almost on top of the $71.72 support, so the horizontal floor and the dynamic average reinforce each other, and the $71.00 stop is anchored just beneath both. The honest nuance is that price still trades just below the 200-week SMA ($76.36), and the $77.20 horizontal sits just above it. A weekly close above $77.20 would clear the 200-week average and that ceiling together, which explains why the breakout buy level sits where it does. With the daily triangle breakout and the weekly downtrend break firing in the same week, the timeframes are aligned, and that agreement carries more weight than either signal alone.

GEHC – Weekly Chart

#6 Bullish Stochastic: On the weekly stochastic, %K (87.85) has crossed above %D (73.77). The upturn began from the low-30s, near the lower end of the range, during September and October, so this is a full momentum swing rather than a minor wiggle. Weekly crossovers carry meaningfully more weight than daily ones because each bar compresses a full week of price discovery, so the signal reflects a durable shift rather than intraweek noise. The honest nuance is that %K has already pushed above 80, confirming buyers are in firm control but also showing the near-term move is stretched. In strong trends, weekly stochastic can stay overbought for several weeks, so the reading argues for buying dips rather than avoiding the stock. It reinforces the case for the $74.00 pullback entry over chasing strength.

#7 Bullish Aroon: The weekly Aroon has snapped into its strongest possible bullish configuration: Aroon Up at 100% and Aroon Down at 0%. Aroon Up at its ceiling means GEHC has just printed a fresh 14-week high. This week’s $77.88 peak cleared the August swing high, consistent with the breakout seen across both charts. Aroon Down at 0% means the most recent 14-week low is as far back as the lookback allows, so sellers have failed to set a new low in more than three months. The Aroon Up line had decayed toward 40% before rocketing back to 100%, which marks a renewed uptrend impulse rather than a stale reading carried over from the summer. The maximum separation between the two lines confirms there is no internal conflict in the trend at this stage.

Risks to Consider

Even strong setups can fail, especially in a large-cap medical technology stock like GE HealthCare that just gapped sharply higher on earnings. A few things could knock the stock off course:

• A breakdown back inside the symmetrical triangle — and below the $71.72 weekly support area — on heavy volume would invalidate the breakout thesis
• Post-earnings profit-taking, negative company news, or broader market weakness — after a +6.62% gap that lifted the stock above several pre-earnings analyst targets, any disappointment in follow-through orders or margins could trigger a pullback
• Tariffs and component inflation — memory, freight, and other input costs remain headwinds, and Q3 free cash flow included a one-time $55 million tariff refund, so not all of the $793 million should be treated as recurring
• Leverage — roughly $10.0 billion of debt against $2.9 billion of cash (about $7.1 billion net) limits flexibility as GEHC pursues acquisitions
• Patient Care Solutions uncertainty — management is evaluating strategic options for the unit while installing a new leader, and its organic revenue is still down 4.5% for the first nine months of 2026
• SOFIE integration risk — the $945 million cash deal still needs regulatory approval, carries execution risk, and its FAPI-74 tracer remains a late-stage pipeline asset rather than an approved product
• Regulatory and adoption risk — StarGuide GX is still awaiting FDA clearance, and uptake of new scanners, AI software, and imaging drugs could be slower than expected
• Hospital budgets and competition — large equipment orders are sensitive to hospital capital budgets and procurement cycles (particularly in China), and GEHC faces stiff competition from Siemens Healthineers, Philips, and Canon Medical

The Bottom Line

GEHC is breaking out of a months-long symmetrical triangle on the daily chart while also clearing a downtrend line and reclaiming a key support area on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.

The fundamental story underneath the chart is just as strong: a beat-and-raise third quarter, adjusted EPS up 25.1%, and a $23.7 billion order backlog.

Combine that with multiple catalysts staggered through year-end and into 2027 — the Patient Care Solutions leadership handoff on November 16, RSNA 2026 in early December, a pending FDA decision on StarGuide GX, Q4 results and 2027 guidance, and the expected SOFIE closing in the first half of 2027 — and GEHC looks like one of the more compelling risk-reward setups on the board right now.

If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our two entry options — a breakout entry and a pullback entry — along with both price targets that imply 14%–30% potential upside depending on your entry, and the stop-losses we’re using to manage the downside.

Recommended Trade Setup

After Wednesday’s gap, GEHC is trading roughly 8%–11% above its 50-day and 200-day moving averages, so we’re offering two ways to play this setup: buy on confirmation above $77.20, or wait for a healthier retest of the gap zone near $74.00.

Option 1: Buy on Breakout

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $6.20 per share, the target rewards are about $10.80 and $18.80 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Note on Trade Invalidation: This recommendation stays active as long as the technical structure holds. If GEHC drops to or below the $71.00 stop-loss before the $77.20 entry triggers, the trade is automatically void — the support underpinning the thesis would have broken, and the risk-reward setup would no longer justify entry. Re-entry should only be considered on a fresh setup with its own risk parameters.

Option 2: Buy on Pullback

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $7.00 per share, the target rewards are about $14.00 and $22.00 per share. That makes this a 1:2 and better-than-1:3 risk-reward trade. In other words, the setup offers 2x to 3x more potential upside than downside.

Happy Trading!
Tara and Greg